SERENA-6 研究的全體大會報告將聚焦用於晚期 HR 陽性乳腺癌一線治療的新一代口服 SERD 藥物 Camizestrant
MATTERHORN 研究的全體大會報告將展示英飛凡用於早期胃和胃食管結合部腺癌的圍手術期治療方案
DESTINY-Breast09 研究的專場口頭報告將強調優赫得在 HER2 陽性轉移性乳腺癌更前線治療的潛力
上海 2025年5月22日 /美通社/ -- 阿斯利康在2025年5月30日至6月3日召開的美國臨牀腫瘤學會（ASCO）上，憑藉行業領先的多樣化產品與管線佈局的全新研究數據，進一步深化自身讓癌症不再成爲致死主因的雄心。
會上將有超過80個摘要公佈，其中涵蓋20款已獲得批准的藥物和潛在新藥，包括兩項重磅研究的全體大會報告（plenary presentation），一項特別重磅研究摘要口頭報告（late-breaking oral abstract session），以及19項口頭報告。其中亮點包括：
阿斯利康全球執行副總裁、全球腫瘤研發負責人高書璨（ Susan Galbraith）表示："本次ASCO大會上公佈的兩項乳腺癌重磅研究數據將凸顯我們在以創新藥物和產品管線改變腫瘤治療結局上所取得的進展。SERENA-6是首個採用循環腫瘤DNA檢測指導治療方案切換的一項關鍵III期臨牀研究，開創了這一技術在一線治療中的應用，以延緩HR陽性、HER2陰性晚期乳腺癌的疾病進展。此外，DESTINY-Breast09研究評估了德曲妥珠單抗與帕妥珠單抗的聯合治療方案，這是十年來首次在HER2陽性轉移性乳腺癌廣泛患者羣體中，證明療效優於目前一線治療標準方案的試驗。"
阿斯利康全球執行副總裁，全球腫瘤研發負責人Dave Fredrickson表示："MATTERHORN的研究數據證明，度伐利尤單抗作爲胃和胃食管結合部腺癌患者圍手術期的治療方案，是我們將免疫療法遷入癌症早期階段治療的成功例證，有望實現早期治癒的可能。這是阿斯利康連續第七年登上ASCO全體大會，這一非凡的里程碑彰顯出我們在多個癌腫領域已建立行業領先的腫瘤產品組合和強大的研發管線。
阿斯利康與第一三共聯合開發和商業化德曲妥珠單抗與Datroway；與默沙東（默沙東是美國新澤西州羅威市默克公司的公司商號）聯合開發和商業化司美替尼；與和黃醫藥合作開發和商業化賽沃替尼。
阿斯利康在 2025 年 ASCO 大會期間的重要演講 1
| 主要作者 | 摘要標題 | 演示文稿詳情 (CDT) |
| 抗體偶聯藥物 | ||
| Shitara, K | Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. | Abstract #LBA4002 Oral Abstract Session 31 May 2025 3:24pm |
| Tolaney, SM | Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line(1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | Abstract #LBA1008 Oral Abstract Session 2 June 2025 7:30am |
| Dent, R | Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in HER2-low/-ultralow, hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06). | Abstract #1013 Oral Abstract Session 31 May 2025 3:23pm |
| Levy, BP | TROPION-Lung02: Datopotamab deruxtecan(Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). | Abstract #8501 Oral Abstract Session 1 June 2025 8:12am |
| Waqar, SN | First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). | Abstract #8521 Poster Session 31 May 2025 1:30pm |
| 腫瘤驅動因素和耐藥性 | ||
| Turner, NC | Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. | Abstract #LBA4 Plenary Session 1 June 2025 2:41pm |
| Lu, S | Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) andMET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. | Abstract #LBA8505 Oral Abstract Session 1 June 2025 9:48am |
| Levy, BP | Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO). | Abstract #8513 Rapid Oral Abstract Session 2 June 2025 8:06am |
| Chaft JE | Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA. | Abstract #8001 Oral Abstract Session 2 June 2025 3:12pm |
| 免疫腫瘤學與雙特異性抗體 | ||
| Janjigian, YY | Event-free survival in MATTERHORN: a randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). | Abstract #LBA5 Plenary Session 1 June 2025 3:13pm |
| Powles, T | Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA | Abstract #4503 Oral Abstract Session 1 June 2025 10:45am |
| Reck, M | Associations of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial. | Abstract #8009 Rapid Oral Abstract Session 1 June 2025 4:30pm |
| Barbie, DA | Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC). | Abstract #8014 Rapid Oral Abstract Session 1 June 2025 5:12pm |
| Mayadev, J | Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses. | Abstract #5502 Oral Abstract Session 2 June 2025 8:48am |
| Westin, SN | Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA. | Abstract #5512 Rapid Oral Abstract Session 3 June 2025 8:30am |
| Erinjeri, JP | Outcomes by baseline tumor burden using the 6-and-12 score in EMERALD-1: a phase 3 study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolization (TACE) in embolization-eligible unresectable hepatocellular carcinoma (uHCC). | Abstract #4083Poster Session 31 May 2025 9:00am |
| Cascone, T | Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectablenon-small-cell lung cancer(NSCLC): Updated outcomes from NeoCOAST-2. | Abstract #8046 Poster Session 31 May 2025 1:30pm |
| Zhou, J | First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A. | Abstract #4080 Poster Session 31 May 2025 9:00am |
| Xu, R | ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC). | Abstract #TPS4204 Poster Session 31 May 2025 9:00am |
| Mathias, C | ARTEMIDE-Lung03: a phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1. | Abstract #TPS8653 Poster Session 31 May 2025 1:30pm |
| 細胞療法 | ||
| Yoo, C | RHEA-1: First-in-human (FIH) study of AZD9793, a first-in-class CD8-guided T cell-engager (TCE) for glypican-3-positive (GPC3+) advanced or metastatic hepatocellular carcinoma (HCC). | Abstract #TPS4215 Poster Session 31 May 2025 9:00am |
| Kim, TM | Safety and Efficacy of AZD0486, a CD19xCD3 T-cell Engager, in Relapsed or Refractory Diffuse Large B-cell Lymphoma. | Abstract #7046Poster Session 1 June 2025 9:00am |
| Shadman, M | TITANium: An open-label, global multicenter Phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. | Abstract #TPS7091 Poster Session 1 June 2025 9:00am |
| Le Gouill, S | SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or Combination Therapy in Patients With Mature B-cell Malignancies. | Abstract #TPS7083 Poster Session 1 June 2025 9:00am |
| 罕見病藥物 | ||
| Chen, AP | Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a Phase 3, international, randomized, placebo-controlled study. | Abstract #3014 Rapid Oral Abstract Session 2 June 2025 8:00am |
| 1 阿斯利康在2025年ASCO大會將公佈超過80個摘要，涵蓋其產品和管線中的分子藥物 |
關於阿斯利康腫瘤領域的研究
阿斯利康正引領着腫瘤領域的一場革命，致力提供多元化的腫瘤治療方案，以科學探索腫瘤領域的複雜性，發現、研發並向患者提供改變生命的藥物。
阿斯利康專注於最具挑戰性的腫瘤疾病，通過持續不斷的創新，阿斯利康已經建立了行業領先的多元化的產品組合和管線，持續推動醫療實踐變革，改變患者體驗。
阿斯利康以期重新定義癌症治療並在未來攻克癌症。
關於阿斯利康
阿斯利康（LSE/STO/Nasdaq: AZN）是一家科學至上的全球生物製藥企業，專注於研發、生產及營銷處方類藥品，重點關注腫瘤、罕見病以及包括心血管腎臟及代謝、呼吸及免疫在內的生物製藥等領域。阿斯利康全球總部位於英國劍橋，業務遍佈超過125個國家，創新藥物惠及全球數百萬患者。更多信息，請訪問。
關於阿斯利康中國
阿斯利康自1993年進入中國以來，專注中國患者需求最迫切的治療領域，包括腫瘤、心血管、腎臟、代謝、呼吸、消化、罕見病、疫苗抗體及自體免疫等，已將40多款創新藥物帶到中國。阿斯利康中國總部位於上海，並在上海和北京設立全球戰略研發中心，在北京、廣州、杭州、成都、青島設立區域總部，在無錫、泰州、青島建立全球生產供應基地，向全球70多個市場輸送優質創新藥品。
聲明：本文研究中涉及的多種藥品用法尚未在中國獲批適應症，阿斯利康不推薦任何未被批准的藥品使用。
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。